Menu

Plan to Fight Zika with GM Mosquitoes Passes Popular Vote in Florida

The strategy to release mosquitoes that cannot spread the virus passed a county-level vote but faced opposition in one town. 

Nov 10, 2016
Ben Andrew Henry

CDC

An embattled plan to slow the spread of the Zika virus by releasing genetically modified (GM) mosquitoes passed a popular vote in one Florida county on Tuesday (November 8). A trial implementation of the strategy, which effectively cut down mosquito populations in early tests outside the state, was approved by the US Food and Drug Administration in August but faced vocal opposition by some Florida residents.

In nonbinding “straw polls,” 58 percent of residents of Monroe County approved the strategy. In a separate poll, however, residents of Key Haven, a town within Monroe County where the mosquitoes would be deployed, soundly rejected the proposal, with 65 percent voting against it.

The final decision will be left up to the Florida Keys Mosquito Control District Board, which will convene on November 19 to weigh public opinion, BBC News reported. Phil Goodman, chairman of the Florida Keys Mosquito Control District, told Wired that the plan will move forward in accordance with the county vote, but officials will seek a site other than Key Haven to implement the trial.

However, Derric Nimmo, who is leading the trial for the Oxitec, the British biotech company that designed the mosquitoes, told the BBC that “Key Haven was chosen about four years ago based on the fact that it’s surrounded by water and it’s an almost perfect scientific site where you have a control area where you don’t do any releases, an area where you can do releases, and a buffer zone in between.”

The trial would involve releasing male mosquitoes, which have been genetically modified to carry a gene that causes their offspring to die before reproducing, in one neighborhood of Key Haven. Since male mosquitoes do not bite, their release would not increase risk of Zika transmission. To the contrary, their introduction to mosquito populations in early testing reduced population sizes by around 90 percent, according to NPR’s Shots.

“We’ve had six years of releases, involving millions of male mosquitoes, and there have been no reports of any adverse effects,” Nimmo told the BBC. “It’s important we’re as transparent as possible . . . we’ve been trying to give people the facts and information so they can make an informed choice.”

Update (November 22): On November 19, the Mosquito Control District Board voted 3-2 in favor of the field trial, though they have yet to establish a new site to release mosquitoes, STAT News reported.

November 2018

Intelligent Science

Wrapping our heads around human smarts

Marketplace

Sponsored Product Updates

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

The Lab of the Future: Alinity Poised to Reinvent Clinical Diagnostic Testing and Help Improve Healthcare

Every minute counts when waiting for accurate diagnostic test results to guide critical care decisions, making today's clinical lab more important than ever. In fact, nearly 70 percent of critical care decisions are driven by a diagnostic test.

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC announces new, integrated, global portfolio brand, Biosearch Technologies, representing genomic tools for mission critical customer applications

LGC’s Genomics division announced it is transforming its branding under LGC, Biosearch Technologies, a unified portfolio brand integrating optimised genomic analysis technologies and tools to accelerate scientific outcomes.

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN licenses CRISPR-Cas9 gene editing technology from Broad Institute to develop cell models for optimized metabolic disease drug development

DefiniGEN Ltd are pleased to announce the commercial licensing of CRISPR-Cas9 gene-editing technology from Broad Institute of MIT and Harvard in the USA, to develop human cell disease models to support preclinical metabolic disease therapeutic programmes.